S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Price, News & Analysis

$1.18
+0.01 (+0.85%)
(As of 03/28/2024 ET)
Today's Range
$1.15
$1.22
50-Day Range
$0.80
$1.51
52-Week Range
$0.45
$1.88
Volume
1.07 million shs
Average Volume
1.10 million shs
Market Capitalization
$266.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.05

Gossamer Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
582.2% Upside
$8.05 Price Target
Short Interest
Healthy
4.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.75mentions of Gossamer Bio in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$5,344 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.72) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.42 out of 5 stars

Medical Sector

146th out of 938 stocks

Pharmaceutical Preparations Industry

55th out of 426 stocks

GOSS stock logo

About Gossamer Bio Stock (NASDAQ:GOSS)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

GOSS Stock Price History

GOSS Stock News Headlines

Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
GOSS Apr 2024 1.500 put
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
GOSS Apr 2024 1.000 put
Barclays Keeps Their Hold Rating on Gossamer Bio (GOSS)
Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts
Gossamer Bio Inc (GOSS)
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Gossamer Bio Inc.
5 Small-Cap Stocks with High Potential
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.05
High Stock Price Target
$15.00
Low Stock Price Target
$1.25
Potential Upside/Downside
+585.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-179,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.28 per share

Miscellaneous

Free Float
204,152,000
Market Cap
$265.06 million
Optionable
Optionable
Beta
1.73
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Faheem Hasnain (Age 66)
    Co-Founder, CEO, President & Chairman
    Comp: $902.52k
  • Mr. Bryan  GiraudoMr. Bryan Giraudo (Age 49)
    COO & CFO
    Comp: $690.59k
  • Dr. Richard Aranda M.D. (Age 63)
    Chief Medical Officer
    Comp: $625.24k
  • Mr. Christian Waage (Age 57)
    Executive Vice President of Technical Operations & Administration
    Comp: $583.16k
  • Mr. Jeff Boerneke
    General Counsel & Secretary
  • Ms. Deanna Weber
    Senior Vice President of Human Resources
  • Mr. Mario Orlando
    Senior Vice President of Commercial New Product Planning
  • Ms. Caryn L. Peterson (Age 65)
    Executive Vice President of Regulatory Affairs
  • Mr. Matt Cravets
    Senior Vice President of Biometrics
  • Dr. Lisa Elizabeth Nolan Ph.D. (Age 62)
    MD & President of Gossamer Bio Ireland

GOSS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GOSS shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price target for 2024?

5 analysts have issued 1-year price targets for Gossamer Bio's stock. Their GOSS share price targets range from $1.25 to $15.00. On average, they predict the company's stock price to reach $8.05 in the next twelve months. This suggests a possible upside of 582.2% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2024?

Gossamer Bio's stock was trading at $0.9125 at the beginning of the year. Since then, GOSS shares have increased by 29.3% and is now trading at $1.18.
View the best growth stocks for 2024 here
.

Are investors shorting Gossamer Bio?

Gossamer Bio saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 11,090,000 shares, a decline of 22.4% from the February 29th total of 14,300,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 10.3 days.
View Gossamer Bio's Short Interest
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) posted its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21).

What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.16%), Vanguard Group Inc. (5.16%), Octagon Capital Advisors LP (4.08%), Platinum Investment Management Ltd. (3.09%), Palo Alto Investors LP (2.64%) and Madison Avenue Partners LP (2.24%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GOSS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners